PCRX Logo

Pacira BioSciences, Inc. (PCRX) 

NASDAQ
Market Cap
$799.72M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
182 of 774
Rank in Industry
7 of 47

Largest Insider Buys in Sector

PCRX Stock Price History Chart

PCRX Stock Performance

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that …

Insider Activity of Pacira BioSciences, Inc.

Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $4.28M worth of Pacira BioSciences, Inc. stock.

On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $153,467 and sold $17.4M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lee Frank D. (Chief Executive Officer) — $99,994. BIGAL MARCELO (director) — $60,868. YANG MICHAEL J. (director) — $51,600.

The last purchase of 1,512 shares for transaction amount of $20,034 was made by BIGAL MARCELO (director) on 2024‑08‑16.

List of Insider Buy and Sell Transactions, Pacira BioSciences, Inc.

2024-09-13SaleChief Operating Officer
500
0.0011%
$12.86$6,430+25.48%
2024-08-16Purchasedirector
1,000
0.0023%
$12.81$12,810+9.13%
2024-08-16Purchasedirector
1,512
0.0036%
$13.25$20,034+5.51%
2024-08-14Purchasedirector
2,000
0.0046%
$12.90$25,8000.00%
2024-08-12PurchaseChief Executive Officer
8,264
0.0178%
$12.10$99,994+26.28%
2024-08-12Purchasedirector
1,400
0.0029%
$11.58$16,212+26.28%
2024-08-12Purchasedirector
3,400
0.0073%
$12.01$40,834+26.28%
2024-08-02SaleChief Medical Officer
945
0.0019%
$20.05$18,947-26.88%
2024-07-02SaleChief Medical Officer
2,836
0.0062%
$28.25$80,1170.00%
2024-06-13SaleChief Operating Officer
1,000
0.0021%
$28.38$28,380-41.89%
2024-06-13SaleChief Administrative Officer
7,452
0.0157%
$28.38$211,488-41.89%
2024-06-13Saledirector
880
0.0019%
$28.38$24,974-41.89%
2024-06-12SaleSenior Vice President, Finance
3,970
0.0085%
$28.72$114,018-42.40%
2024-06-11SaleChief Medical Officer
5,012
0.0106%
$28.57$143,193-42.89%
2024-03-08Saledirector
90,000
0.1889%
$30.60$2.75M-17.04%
2024-03-07Saledirector
28,257
0.0613%
$30.81$870,598-14.89%
2024-03-06Saledirector
1,066
0.0023%
$29.67$31,628-13.22%
2023-08-02SaleChief Medical Officer
509
0.0011%
$34.88$17,751-19.01%
2023-07-05SaleSenior Vice President, Finance
643
0.0014%
$38.91$25,019-22.50%
2023-06-14SaleChief Administrative Officer
6,467
0.0135%
$37.03$239,473-21.58%

Insider Historical Profitability

22.98%
Lee Frank D.Chief Executive Officer
107784
0.2334%
$17.3210
PACE GARY Wdirector
22127
0.0479%
$17.3256+11.64%
Brege Lauradirector
17552
0.038%
$17.3216
Froimson Markdirector
14473
0.0313%
$17.3222<0.0001%
HASTINGS PAUL Jdirector
12724
0.0276%
$17.32118+79.52%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$230.99M16.987.91M-2.58%-$6.11M0.01
The Vanguard Group$149.41M10.995.11M+0.29%+$437,131.20<0.01
Frontier Capital Management Co$55.94M4.111.91M-8.16%-$4.97M0.52
State Street$55.62M4.091.9M-1.68%-$950,994.13<0.01
Renaissance Technologies$55M4.041.88M+9.64%+$4.84M0.09
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.